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I would like to congratulate Shah and Smith for their excellent comprehensive review of

27

phenoconversion [1]. They used a narrow definition of personalized medicine restricted to

28

pharmacogenetics as they described phenoconversion as its Achilles’ heel. A more comprehensive view of

29

personalized medicine and its application for prescribing medication, personalized prescription, considers

30

not only genetic factors but environmental and personal factors [2]. Inhibitors, among environmental

31

factors, and inflammation, among personal factors, can cause phenoconversion to a poor metabolizer (PM)

32

phenotype. Personalized prescription can be implemented as personalized drug selection and personalized

33

dosing [2]. Combining pharmacogenetics and therapeutic drug monitoring (TDM) is the best way for

34

implementing personalized dosing [3]. Moreover, with TDM, phenoconversion is no longer a problem but a

35

helpful piece of additional information.

36

Venlafaxine and risperidone TDM and CYP2D6 genotyping are described as examples. A plasma

37

O-desmethylvenlafaxine/venlafaxine concentration ratio <1 signals the absence of CYP2D6 activity,

38

explained by 1) genetic PM status, or 2) phenoconversion after taking a powerful CYP2D6 inhibitor, or

39

from competitive inhibition after the use of venlafaxine itself [4]. Shah and Smith described them,

40

respectively, as gPM and pPM [1]. Preskorn et al. [4], using this ratio, found that venlafaxine had mild

41

CYP2D6 inhibitory properties and that 21% (159/748) of CYP2D6 extensive metabolizers (EMs)

42

experienced phenoconversion to pPM status. Not unexpectedly, nine subjects with a genotype of CYP2D6

43

*4/*10 (a null allele and an allele with very low activity) had a median ratio of 1.2, since venlafaxine

44

competitively inhibited the very limited CYP2D6 activity they had.

45

A risperidone TDM ratio was first used in psychiatry to detect phenoconversion during a

46

risperidone North American randomized clinical trial (RCT) [5]. CYP2D6 EMs had higher plasma 9-

47

hydroxyrisperidone concentrations than risperidone concentrations. If we then calculate a risperidone/9-

48

hydroxyrisperidone ratio for CYP2D6 EMs, the ratio is <1 [6]. An inverted ratio, with higher

49

concentrations of risperidone than 9-hydroxyrisperidone, occurred in CYP2D6 PMs and was expected in

50

50% of CYP2D6 EMs taking paroxetine or fluoxetine [5]. Unfortunately, the RCT risperidone TDM data

3
51

was never published by the company in a peer-review journal but was only presented in a poster. In a

52

review article [7], graphics summarized the TDM data from the RCT by focusing on the mean values of the

53

risperidone/9-hydroxyrisperidone ratio and the total concentration-to-dose ratio (C/D ratio), a measure of

54

risperidone clearance from the body. The total concentration is calculated by adding the risperidone and 9-

55

hydroxyrisperidone plasma concentrations [7].

56

In a naturalistic study of risperidone pharmacogenetics, 277 patients provided risperidone TDM

57

data [8]. Table 1 shows that an inverted ratio (risperidone/9-hydoxirisperidone ratio >1) was present in

58

almost every CYP2D6 gPM, 95% (19/20) versus 15% (39/257) for the rest of the patients.

59

Phenoconversion was particularly frequent, 83% (5/6), in the intermediate metabolizers [IMs] taking

60

CYP2D6 inhibitors.

61

A clobazam TDM ratio may also be used to establish phenoconversion. After reviewing the

62

clobazam literature, we have proposed that a steady-state plasma N-desmethylclobazam/clobazam ratio >25

63

will identify a CYP2C19 gPM as long as CYP2C19 inhibitors are absent [9]. Interpreting clozapine TDM is

64

more complex, requiring stratification by smoking and gender because they influence CYP1A2 activity. A

65

clozapine concentration/dose ratio of >1.20 in a US female non-smoker is suggestive of poor clozapine

66

metabolism [10].

67
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Table 1. Frequency of inverted ratios in risperidone TDM study with 277 patients
Frequency of inverted ratios1
Total sample
On inhibitors2 No inhibitors
CYP2D6 genotyping3
gPMs
95% (19/20)
Non gPMs
15% (39/257)4
63% (27/43)4 6% (12/214)4
4
gIMs
43% (13/30)
83% (5/6)4 33% (8/24)4
gEMs
12% (26/219)4
61% (22/36)4,5 2% (4/183)4
gUMs
0% (0/8)
0% (0/1)
0% (0/7)
1
Another factor influencing an inverted ratio was body weight. After excluding the CYP2D6 gPMs, a
logistic regression analysis of R/9-OHR >1 was performed. The significant variables were the number of
CYP2D6 active alleles (odds ratio OR=0.18, 99% confidence interval, 0.08, 0.43), use of CYP inhibitors
(OR=16.7; 6.2, 44.9), and body weight higher than the sample mean (OR=0.27, 0.10, 0.69).
2
Bupropion, fluoxetine or paroxetine. Bupropion is a moderate CYP2D6 inhibitor; paroxetine and
fluoxetine are potent CYP2D6 inhibitors.
3
g refers to genetic. This is the terminology proposed by Shah and Smith [1].
4
Any patient who is not a gPM and has an inverted ratio would be a pPM according to the terminology
proposed by Shah and Smith [1].
5
Phenoconversion is influenced by CYP2D6 genotype. In the 36 gEMs on inhibitors, the frequency of
inverted ratios was 61%, but the prevalence varied according to the number of active alleles: 80% (12/15)
in those with 1.0 active allele, 71% (5/7) in those with 1.4 active alleles, and 36% (5/14) in those with 2.0
active alleles.

